Marszal E - Search Results

1

AFM Imaging Reveals Topographic Diversity of Wild Type and Z Variant Polymers of Human α1-Proteinase Inhibitor.

Gaczynska M, Karpowicz P, Stuart CE, Norton MG, Teckman JH, Marszal E, Osmulski PA. Gaczynska M, et al. Among authors: marszal e. PLoS One. 2016 Mar 23;11(3):e0151902. doi: 10.1371/journal.pone.0151902. eCollection 2016. PLoS One. 2016. PMID: 27008547 Free PMC article.

2

Subvisible Particle Content, Formulation, and Dose of an Erythropoietin Peptide Mimetic Product Are Associated With Severe Adverse Postmarketing Events.

Kotarek J, Stuart C, De Paoli SH, Simak J, Lin TL, Gao Y, Ovanesov M, Liang Y, Scott D, Brown J, Bai Y, Metcalfe DD, Marszal E, Ragheb JA. Kotarek J, et al. Among authors: marszal e. J Pharm Sci. 2016 Mar;105(3):1023-7. doi: 10.1016/S0022-3549(15)00180-X. Epub 2016 Feb 3. J Pharm Sci. 2016. PMID: 26886324

3

A novel mode of polymerization of alpha1-proteinase inhibitor.

Marszal E, Danino D, Shrake A. Marszal E, et al. J Biol Chem. 2003 May 30;278(22):19611-8. doi: 10.1074/jbc.M210720200. Epub 2003 Mar 20. J Biol Chem. 2003. PMID: 12649292 Free article.

4

Serpin crystal structure and serpin polymer structure.

Marszal E, Shrake A. Marszal E, et al. Arch Biochem Biophys. 2006 Sep 1;453(1):123-9. doi: 10.1016/j.abb.2006.03.006. Epub 2006 Mar 23. Arch Biochem Biophys. 2006. PMID: 16631102 Review.

5

Physical Characterization and Innate Immunogenicity of Aggregated Intravenous Immunoglobulin (IGIV) in an In Vitro Cell-Based Model.

Moussa EM, Kotarek J, Blum JS, Marszal E, Topp EM. Moussa EM, et al. Among authors: marszal e. Pharm Res. 2016 Jul;33(7):1736-51. doi: 10.1007/s11095-016-1914-4. Epub 2016 Apr 1. Pharm Res. 2016. PMID: 27037576

6

Characterization of differences in isoelectric focusing behavior of alpha-proteinase inhibitor products.

Marszal E, Shrake A. Marszal E, et al. Transfusion. 2006 May;46(5):872-3; author reply 874. doi: 10.1111/j.1537-2995.2006.00809.x. Transfusion. 2006. PMID: 16686863 No abstract available.

7

Workshop on predictive science of the immunogenicity aspects of particles in biopharmaceutical products.

Marszal E, Fowler E. Marszal E, et al. J Pharm Sci. 2012 Oct;101(10):3555-9. doi: 10.1002/jps.23243. Epub 2012 Jun 26. J Pharm Sci. 2012. PMID: 22736535

8

Analyzing subvisible particles in protein drug products: a comparison of dynamic light scattering (DLS) and resonant mass measurement (RMM).

Panchal J, Kotarek J, Marszal E, Topp EM. Panchal J, et al. Among authors: marszal e. AAPS J. 2014 May;16(3):440-51. doi: 10.1208/s12248-014-9579-6. Epub 2014 Feb 26. AAPS J. 2014. PMID: 24570341 Free PMC article.

9

Meeting report on protein particles and immunogenicity of therapeutic proteins: filling in the gaps in risk evaluation and mitigation.

Carpenter J, Cherney B, Lubinecki A, Ma S, Marszal E, Mire-Sluis A, Nikolai T, Novak J, Ragheb J, Simak J. Carpenter J, et al. Among authors: marszal e. Biologicals. 2010 Sep;38(5):602-11. doi: 10.1016/j.biologicals.2010.07.002. Epub 2010 Aug 11. Biologicals. 2010. PMID: 20702108

10

An international collaborative study to establish the WHO 1st international standard for alpha-1-antitrypsin.

Thelwell C, Marszal E, Rigsby P, Longstaff C. Thelwell C, et al. Among authors: marszal e. Vox Sang. 2011 Jul;101(1):83-9. doi: 10.1111/j.1423-0410.2010.01459.x. Epub 2010 Dec 22. Vox Sang. 2011. PMID: 21668863

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

92 results

Search Page